Search our Database of Scientific Publications and Authors

I’m looking for a

    18171 results match your criteria Botulinum Toxin

    1 OF 364

    Obesity Treatment with Botulinum Toxin-A Is Not Effective: a Systematic Review and Meta-Analysis.
    Obes Surg 2017 Aug 15. Epub 2017 Aug 15.
    Gastrointestinal Endoscopy Unit, Hospital das Clinicas, University of São Paulo Medical School, Dr. Arnaldo Av, 455, São Paulo, 01246-903, Brazil.
    The effectiveness of gastric injections of botulinum toxin-A (BTA) as primary treatment for obesity is not well known since results in literature are discrepant. Hence, we aimed to systematically review and meta-analyze the available data to assess the real effect of BTA therapy. We searched MEDLINE, Embase, Cochrane, SCOPUS, EBSCO, LILACS, and BVS. Read More

    Ultrasound guided injections of botulinum toxin type A into stellate ganglion to treat insomnia.
    Exp Ther Med 2017 Aug 15;14(2):1136-1140. Epub 2017 Jun 15.
    Department of Rehabilitation Medicine, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei 441000, P.R. China.
    The aim of the study was to investigate the curative effect of botulinum toxin type A (BTX-A) injection into stellate ganglion under ultrasound guidance in patients suffering from insomnia. From October 2015 to April 2016, 48 patients suffering from insomnia were enrolled in this study. Patients were divided into 2 groups using a random digital grouping method: i) Control group (24 cases), and ii) treatment group (24 cases). Read More

    Treatment of Inverse/Intertriginous Psoriasis: Updated Guidelines from the Medical Board of the National Psoriasis Foundation.
    J Drugs Dermatol 2017 Aug;16(8):760-766

    Inverse or intertriginous psoriasis commonly involves skin fold areas including the axillae, perianal skin, intergluteal cleft, inframammary, genital/inguinal, abdominal, and retroauricular folds. After reviewing the literature for new treatments, a task force was convened to update a consensus on inverse psoriasis therapy. Short-term treatment continues to be low-potency topical steroids. Read More

    Neurotoxin synthesis is positively regulated by the sporulation transcription factor Spo0A in Clostridium botulinum type E.
    Environ Microbiol 2017 Aug 15. Epub 2017 Aug 15.
    Department of Food Hygiene and Environmental Health, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.
    Clostridium botulinum produces the most potent natural toxin, the botulinum neurotoxin (BoNT), probably to create anaerobiosis and nutrients by killing the host, and forms endospores that facilitate survival in harsh conditions and transmission. Peak BoNT production coincides with initiation of sporulation in C. botulinum cultures, which suggests common regulation. Read More

    The colorful spectrum of Tourette syndrome and its medical, surgical and behavioral therapies.
    Parkinsonism Relat Disord 2017 Aug 10. Epub 2017 Aug 10.
    Dept. of Neurology and Center of Clinical Neuroscience, First Medical Faculty, Charles University and General Hospital in Prague, Kateřinská 30, 120 00, Czech Republic. Electronic address:
    Tourette syndrome (TS) is a common neuropsychiatric disorder, more common in males than females, with onset before age 18. TS is characterized by multiple motor tics and one or more vocal/phonic tics, persisting for more than a year. Tics are unvoluntary, abrupt, rapid, repetitive, but non-rhythmic movements or sounds (vocalizations). Read More

    Fibromatosis Colli: A Case Report.
    Oman Med J 2012 Nov;27(6):e011
    Resident, Department of Ophthalmology, J N Medical College, AMU, Aligarh, India.
    Fibromatosis colli or sternocleidomastoid tumor of infancy is a condition of benign proliferation of fibrous tissue within the sternocleidomastoid muscle leading to focal or diffuse enlargement of the sternocleidomastoid muscle and is often clinically associated with torticollis. Radiological imaging especially ultrasound, if performed by an expert radiologist plays an important role in differentiating this benign condition from other causes of neck masses in this age group, thereby preventing unnecessary investigations in a neonate and decreasing parent`s anxiety. We hereby, present a case report of a sternomastoid tumor in a two week old neonate diagnosed using high frequency ultrasound, signifying that every physician should be aware of this clinical entity in a neonate and refer them immediately for ultrasound. Read More

    Botulinum toxin use in rehabilitation clinics: a survey to highlight differences and similarities.
    Int J Rehabil Res 2017 Aug 11. Epub 2017 Aug 11.
    Department of Rehabilitation Medicine, Osborn Neurorehabilitation Unit, Sheffield Teaching Hospitals, Sheffield, UK.
    Spasticity is a complex condition and its management is multifaceted, involving physical therapies as well as interventions with botulinum toxin. There is currently no standard for best practice and also wide variation in spasticity service set-ups and the background of clinicians involved in treatment. This could potentially cause large differences in practice. Read More

    [Mapping of motor-points in the flexor muscles of the arm for the optimization of botulinum toxin injections in treatment of spasticity].
    Zh Nevrol Psikhiatr Im S S Korsakova 2017 ;117(7):47-52
    Best Clinic, Moscow, Russia.
    Aim: To study the location and verification of motor points (MP) of the upper limbs for targeting botulinum toxin (BT) type A injections in the treatment of spasticity.

    Material And Methods: Twenty healthy people were examined. Using electromyography a complete study of the muscles of the upper limbs was conducted. Read More

    Botulinum Toxin Therapy for Nonmotor Aspects of Parkinson's Disease.
    Int Rev Neurobiol 2017 9;134:1111-1142. Epub 2017 Jun 9.
    The Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom.
    The medical treatment of Parkinson's disease (PD) is symptomatic both in terms of motor and nonmotor aspects. The nonmotor symptoms therapy should be taken into account as many of them negatively influence the quality of life and are treatable. Botulinum neurotoxin (BoNT) offers effective treatment for drooling and bladder dysfunctions and alternative treatment for constipation and pain related to parkinsonism. Read More

    Botulinum neurotoxin C mutants reveal different effects of syntaxin or SNAP-25 proteolysis on neuromuscular transmission.
    PLoS Pathog 2017 Aug 11;13(8):e1006567. Epub 2017 Aug 11.
    Department of Biomedical Sciences, University of Padova, Padova, Italy.
    Botulinum neurotoxin serotype C (BoNT/C) is a neuroparalytic toxin associated with outbreaks of animal botulism, particularly in birds, and is the only BoNT known to cleave two different SNARE proteins, SNAP-25 and syntaxin. BoNT/C was shown to be a good substitute for BoNT/A1 in human dystonia therapy because of its long lasting effects and absence of neuromuscular damage. Two triple mutants of BoNT/C, namely BoNT/C S51T/R52N/N53P (BoNT/C α-51) and BoNT/C L200W/M221W/I226W (BoNT/C α-3W), were recently reported to selectively cleave syntaxin and have been used here to evaluate the individual contribution of SNAP-25 and syntaxin cleavage to the effect of BoNT/C in vivo. Read More

    Study of response of Swiss Webster mice to light subunit of mushroom tyrosinase.
    Biotech Histochem 2017 Aug 11:1-6. Epub 2017 Aug 11.
    b Research group of Pharmaceutics, School of Pharmacy , Bandung Institute of Technology , Bandung.
    The light subunit of mushroom, Agaricus bisporus, tyrosinase (LSMT), has been identified as an extrinsic component of the enzyme. Its function is unknown, but it can cross an epithelial cell layer, which suggests that it can be absorbed by the intestine. A similar capability has been demonstrated for the HA-33 component of the progenitor toxin from Clostridium botulinum, which is the closest structural homolog of LSMT. Read More

    Non-invasive Brain stimulation might act in Synergy with Invasive Brain Stimulation in Dystonia.
    Eur J Neurol 2017 Aug 11. Epub 2017 Aug 11.
    Department of Neurology, University Medical Center Groningen, Hanzeplein 1, P. O. Box 30.001, 9700 RB, Groningen, The Netherlands.
    Dystonia is a disabling disorder for which, in the far majority of cases, no curative treatment is available. Current treatment consists medication, botulinum toxin injections and Deep Brain Stimulation (DBS), which all have their own limitations. This article is protected by copyright. Read More

    Cellular Entry of Clostridium perfringens Iota-Toxin and Clostridium botulinum C2 Toxin.
    Toxins (Basel) 2017 Aug 11;9(8). Epub 2017 Aug 11.
    Department of Microbiology, Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Yamashiro-cho, Tokushima 770-8514, Japan.
    Clostridium perfringens iota-toxin and Clostridium botulinum C2 toxin are composed of two non-linked proteins, one being the enzymatic component and the other being the binding/translocation component. These latter components recognize specific receptors and oligomerize in plasma membrane lipid-rafts, mediating the uptake of the enzymatic component into the cytosol. Enzymatic components induce actin cytoskeleton disorganization through the ADP-ribosylation of actin and are responsible for cell rounding and death. Read More

    Single-dose botulinum toxin type a compared with repeated-dose for treatment of trigeminal neuralgia: a pilot study.
    J Headache Pain 2017 Aug 10;18(1):81. Epub 2017 Aug 10.
    Department of Neurology, First Affiliated Hospital of Zhengzhou University, 1 Jianshe East R, Zhengzhou City, HeNan Province, 450052, People's Republic of China.
    Background: Several RCT studies including ours, seem to prove the role of Botulinum toxin type A (BTX-A) in the treatment of trigeminal neuralgia (TN), but no standardized dosing regimen has been established. In our study, we compare two different methods of administration: single-dose or repeated-dose strategy which was most frequently applied over the years in our centre.

    Methods: An open-label trail was conducted. Read More

    Patient treatment preferences for symptomatic refractory urodynamic idiopathic detrusor overactivity.
    Urol Ann 2017 Jul-Sep;9(3):249-252
    Department of Urology, University College London Hospital, London, W1G 8PH, UK.
    Introduction: There is a multiplicity of treatments currently available for patients with symptomatic refractory urodynamic idiopathic detrusor overactivity (SRU IDO). We have assessed patient treatment preferences and their outcomes over a 12-month period from January 1 2009 to December 31 2009.

    Patients And Methods: A retrospective database of all patients with SRU IDO was reviewed for patient demographics, treatment preference, and outcome. Read More

    mRNA mediates passive vaccination against infectious agents, toxins, and tumors.
    EMBO Mol Med 2017 Aug 9. Epub 2017 Aug 9.
    CureVac AG, Tübingen, Germany
    The delivery of genetic information has emerged as a valid therapeutic approach. Various reports have demonstrated that mRNA, besides its remarkable potential as vaccine, can also promote expression without inducing an adverse immune response against the encoded protein. In the current study, we set out to explore whether our technology based on chemically unmodified mRNA is suitable for passive immunization. Read More

    Non-surgical treatment for eyelid retraction in thyroid eye disease (TED).
    Br J Ophthalmol 2017 Aug 9. Epub 2017 Aug 9.
    Scheie Eye Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
    Thyroid eye disease (TED) is an autoimmune condition with an unpredictable course that may lead to permanent facial disfigurement. Eyelid retraction is one of the most common findings, and frequently demands attention due to ocular exposure and impaired cosmesis. Surgical treatment remains the most effective option, but there is a role for temporary corrections during the active phase of the disease, as well as in patients who are poor surgical candidates. Read More

    Centrally mediated late motor recovery after Botulinum toxin injection: Case reports and a review of current evidence.
    J Rehabil Med 2017 Aug 9. Epub 2017 Aug 9.
    Department of Physical Medicine and Rehabilitation, University of Texas Health Science Center at Houston McGovern Medical School and TIRR Memorial Hermann, , Houston, Texas, USA.
    Objective: Botulinum neurotoxin is commonly utilized in neurorehabilitation as a treatment for focal spasticity. Clinical experience has yielded observations of late motor recovery after intramuscular injection of botulinum neurotoxin, that are not readily explained by the classical mechanism of action of the neurotoxin in controlling spasticity. These findings have triggered speculation regarding a botulinum neurotoxin mediated effect at the central level after peripheral intervention. Read More

    Evaluation of articular disc loading in the temporomandibular joints after prosthetic and pharmacological treatment in model studies.
    Adv Clin Exp Med 2017 May-Jun;26(3):455-460
    Department of Prosthodontics, Jagiellonian University Medical College, Kraków, Poland.
    Background: Temporomandibular joint dysfunction is often related to excessive load in the stomatognathic system.

    Objectives: The objective of the model tests, using numeric calculations, was to assess the articular disc loads in the temporomandibular joints after prosthetic and pharmacological treatment of functional disorders of the masticatory organ.

    Material And Methods: The study involved 10 patients, aged 21-48 years, of both sexes, randomly selected from a group of 120 patients treated with relaxation occlusal splints (60 patients, group I) and intramuscular injection of botulinum toxin type A (60 patients, group II), suffering from temporomandibular joint dysfunction with the dominant muscle component. Read More

    Botulinum Toxin in Parkinson Disease Tremor: A Randomized, Double-Blind, Placebo-Controlled Study With a Customized Injection Approach.
    Mayo Clin Proc 2017 Aug 5. Epub 2017 Aug 5.
    Department of Neurology, Yale University School of Medicine, New Haven, CT.
    Background: In essential tremor and Parkinson disease (PD) tremor, administration of onabotulinumtoxinA via a fixed injection approach improves the tremor, but many patients (30%-70%) develop moderate to severe hand weakness, limiting the use of onabotulinumtoxinA in clinical practice.

    Objective: To evaluate the safety and efficacy of incobotulinumtoxinA (IncoA) injection for the treatment of tremor in PD.

    Patients And Methods: In this double-blind, placebo-controlled, crossover trial, 30 patients each received 7 to 12 (mean, 9) IncoA injections into hand and forearm muscles using a customized approach. Read More

    Early Intensive Leg Training to Enhance Walking in Children With Perinatal Stroke: Protocol for a Randomized Controlled Trial.
    Phys Ther 2017 Aug;97(8):818-825
    Department of Physical Therapy, University of Alberta, 2-50 Corbett Hall, Edmonton, Alberta, Canada T6G 2G4; Neuroscience and Mental Health Institute; and Women & Children's Health Research Institute.
    Background: Development of motor pathways is modulated by activity in these pathways, when they are maturing (ie, critical period). Perinatal stroke injures motor pathways, including the corticospinal tracts, reducing their activity and impairing motor function. Current intervention for the lower limb emphasizes passive approaches (stretching, braces, botulinum toxin injections). Read More

    Inhibition of Clostridium botulinum in Model Reduced-Sodium Pasteurized Prepared Cheese Products.
    J Food Prot 2017 Aug 8:1478-1488. Epub 2017 Aug 8.
    2 Kraft Heinz Company, 801 Waukegan Road, Glenview, Illinois 60025, USA.
    The 1986 Food Research Institute-Tanaka et al. model predicts the safety of shelf-stable process cheese spread formulations using the parameters of moisture, pH, NaCl, and disodium phosphate (DSP) to inhibit toxin production by Clostridium botulinum. Although this model is very reliable for predicting safety for standard-of-identity spreads, the effects of additional factors have not been considered. Read More

    A camelid single-domain antibody neutralizes botulinum neurotoxin A by blocking host receptor binding.
    Sci Rep 2017 Aug 7;7(1):7438. Epub 2017 Aug 7.
    Department of Physiology and Biophysics, University of California, Irvine, California, USA.
    Antibody treatment is currently the only available countermeasure for botulism, a fatal illness caused by flaccid paralysis of muscles due to botulinum neurotoxin (BoNT) intoxication. Among the seven major serotypes of BoNT/A-G, BoNT/A poses the most serious threat to humans because of its high potency and long duration of action. Prior to entering neurons and blocking neurotransmitter release, BoNT/A recognizes motoneurons via a dual-receptor binding process in which it engages both the neuron surface polysialoganglioside (PSG) and synaptic vesicle glycoprotein 2 (SV2). Read More

    A Novel Surface Plasmon Resonance Biosensor for the Rapid Detection of Botulinum Neurotoxins.
    Biosensors (Basel) 2017 Aug 7;7(3). Epub 2017 Aug 7.
    Department of Chemistry and Biochemistry, University of Massachusetts Dartmouth, 285 Old Westport Road, North Dartmouth, MA 02747, USA.
    Botulinum neurotoxins (BoNTs) are Category A agents on the NIAID (National Institute of Allergy and Infectious Diseases) priority pathogen list owing to their extreme toxicity and the relative ease of production. These deadly toxins, in minute quantities (estimated human i.v. Read More

    The effects of Botulinum Toxin injection in an elite sportsman with Functional Popliteal Artery Entrapment Syndrome: A case report.
    Phys Ther Sport 2017 Jun 17;27:7-11. Epub 2017 Jun 17.
    Envision Medical Imaging, Wembley, WA, Australia.
    Background: Botulinum Toxin-A (BoNT-A) is an effective intervention for Functional Popliteal Artery Entrapment Syndrome (FPAES) however, concerns with this intervention include reductions in strength and performance.

    Case Report: This case presents an elite male athlete with FPAES who underwent BoNT-A injection and the results of testing before and after injection. The athlete experienced a decrease in strength and performance at one week post-injection however, he returned to baseline levels within four weeks. Read More

    Upregulation of Akt signaling enhances femoral fracture healing by accelerating atrophic quadriceps recovery.
    Biochim Biophys Acta 2017 Aug 1. Epub 2017 Aug 1.
    Department of Orthopaedics, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, 639 Zhizaoju Road, Shanghai 200011, People's Republic of China. Electronic address:
    Muscle damage and disuse muscular atrophy are detrimental for fracture healing. It has been reported that the Akt signaling pathway plays a role in skeletal muscle hypertrophy and atrophy. The aim of this study was to further investigate whether promoting local muscle function through regulating Akt signaling affects fracture healing. Read More

    [Temporal rejuvenation].
    Ann Chir Plast Esthet 2017 Aug 1. Epub 2017 Aug 1.
    281, Corniche Kennedy, 13007 Marseille, France. Electronic address:
    The temporal region has imprecise limits in the young patient. During the aging process, it becomes individualized with the appearance of a temporal fossa, the temporal, orbital and zygomatic bone margins, the ptosis of the lateral part of the brow and the appearance of the wrinkles of the crow's foot. As this area frame the look, it should be taken into consideration during the clinical examination as well as the facial and cervical stages. Read More

    Botulinum Toxin Injections Into the Lateral Cricoarytenoid Muscles for Vocal Process Granuloma.
    J Voice 2017 Aug 1. Epub 2017 Aug 1.
    Drexel University College Of Medicine, Department of Otolaryngology-Head & Neck Surgery, Philadelphia, Pennsylvania.
    Objective: Contact granulomas are benign, exophytic inflammatory lesions of the larynx that typically arise on or near the vocal process of the arytenoid cartilage. The most common management options include voice therapy and antireflux pharmacotherapy, intralesional steroid injections, botulinum toxin injections, and surgical excision. In-office Botox injection into the lateral cricoarytenoid (LCA) muscle can be effective even for recurrent granulomas. Read More

    Platelet-derived growth factor receptor-alpha (PDGFRα) and Ras-related C3 botulinum toxin substrate-1 (Rac1) regulate mechano-responsiveness of lung fibroblasts.
    Am J Physiol Lung Cell Mol Physiol 2017 Aug 3:ajplung.00185.2017. Epub 2017 Aug 3.
    University of Iowa Carver College of Medicine.
    Platelet-derived growth factor (PDGF)-A, which only signals through PDGF-receptor-alpha (PDGFRα) is required for secondary alveolar septal formation. Although PDGFRα distinguishes mesenchymal progenitor cells during the saccular stage, PDGFRα-expressing alveolar cells persist through adulthood. PDGF-A sustains proliferation, limits apoptosis, and maintains alpha-smooth muscle actin (αSMA) containing alveolar cells, which congregate at the alveolar entry ring at postnatal day (P)12. Read More

    Identification and characterization of a novel botulinum neurotoxin.
    Nat Commun 2017 Aug 3;8:14130. Epub 2017 Aug 3.
    Department of Biochemistry and Biophysics, Stockholm University, SE-106 91 Stockholm, Sweden.
    Botulinum neurotoxins are known to have seven serotypes (BoNT/A-G). Here we report a new BoNT serotype, tentatively named BoNT/X, which has the lowest sequence identity with other BoNTs and is not recognized by antisera against known BoNTs. Similar to BoNT/B/D/F/G, BoNT/X cleaves vesicle-associated membrane proteins (VAMP) 1, 2 and 3, but at a novel site (Arg66-Ala67 in VAMP2). Read More

    Long-term stability of reconstituted incobotulinumtoxinA: how can we reduce costs of botulinum toxin therapy?
    J Neural Transm (Vienna) 2017 Aug 2. Epub 2017 Aug 2.
    Toxogen, Hannover, Germany.
    Botulinum neurotoxin (BNT), the biologically active component of botulinum toxin (BT), is a large double-stranded protein susceptible to various physical and chemical influences. All BT type A (BT-A) drugs are stored as powders allowing shelf lives from 24 to 36 months. After reconstitution, the specified shelf life is reduced to 8-24 h. Read More

    A review on use of botulinum toxin for intractable lacrimal drainage disorders.
    Int Ophthalmol 2017 Aug 1. Epub 2017 Aug 1.
    Institute of Anatomy II, Friedrich-Alexander-University, Erlangen-Nürnberg, Germany.
    Purpose: To review the published literature on botulinum toxin (BTX) for epiphora secondary to refractory lacrimal drainage disorders.

    Methods: The authors performed a Pub Med search of all articles published in English on BTX injection into lacrimal gland for epiphora secondary to lacrimal drainage disorders. Relevant cross-references were obtained from the resultant studies. Read More

    Determinants of botulinum toxin discontinuation in multiple sclerosis: a retrospective study.
    Neurol Sci 2017 Aug 1. Epub 2017 Aug 1.
    S. Andrea Hospital, Sapienza University, Via di Grottarossa 1035, 00189, Rome, Italy.
    The purpose of the present study was to investigate the long-term persistence to treatment with botulinum toxin type A (BoNT-A) for multiple sclerosis (MS)-related spasticity and the determinants of BoNT-A discontinuation in daily clinical setting. We retrospectively collected data of patients who started BoNT-A injections and underwent regular follow-up visits. Determinants of BoNT-A discontinuation were explored in a time-to-event Cox regression analysis which included as independent variables a large set of demographic and clinical characteristics. Read More

    Hyperhidrosis Substantially Reduces Quality of Life in Children: A Retrospective Study Describing Symptoms, Consequences and Treatment with Botulinum Toxin.
    Acta Derm Venereol 2017 Aug 1. Epub 2017 Aug 1.
    Hidrosis Clinic, Warfvinges väg 35, SE-112 51 Stockholm, Sweden.
    Studies on children with hyperhidrosis are sparse. This retrospective study presents clinical data and quality of life, along with treatment effect and safety of botulinum toxin (BTX). Case reports from 366 children were included to capture the medical history of hyperhidrosis. Read More

    The Evaluation of the Clinical Effects of Botulinum Toxin on Nocturnal Bruxism.
    Pain Res Manag 2017 5;2017:6264146. Epub 2017 Jul 5.
    Faculty of Dentistry, Department of Oral and Maxillofacial Surgery, Bezmialem Vakıf University, İstanbul, Turkey.
    Objectives: Nocturnal bruxism can be managed by botulinum toxin (Botox®) in patients who have not responded to conservative treatment. The aim of this study was to evaluate the efficacy of botulinum toxin A (BTXA) in the treatment of nocturnal bruxism.

    Material And Methods: The retrospective study comprised 25 female patients, aged 23-55 years (mean 35. Read More

    Botulinun A toxin urethral sphincter injection for neurogenic or nonneurogenic voiding dysfunction.
    Ci Ji Yi Xue Za Zhi 2016 Jul-Sep;28(3):89-93. Epub 2016 Aug 28.
    Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan.
    Voiding dysfunction due to detrusor underactivity or urethral sphincter dysfunction is a treatment challenge for urologists. Recently, urologists have used botulinum toxin A (BoNT-A) injection into the urethral sphincter to treat voiding dysfunction. This treatment has been found to decrease urethral pressure and postvoid residual volume, and increase voiding efficiency in patients with neurogenic detrusor sphincter dyssynergia, nonneurogenic dysfunctional voiding, and detrusor underactivity. Read More

    Effectiveness of botulinum toxin A injection for the treatment of secondary axillary bromhidrosis.
    J Plast Reconstr Aesthet Surg 2017 Jul 8. Epub 2017 Jul 8.
    Department of Plastic and Reconstructive Surgery, Shanghai 9th People's Hospital, Shanghai JiaoTong University School of Medicine, PR China.
    Surgical removal of apocrine glands is a valid treatment option for axillary bromhidrosis. However, malodor may recur after the operation. The value of botulinum toxin A (BTX-A) injection in the treatment of secondary axillary bromhidrosis was investigated in the present study. Read More

    The Effect of Intragastric Administration of Botulinum Toxin Type A on Reducing Adiposity in a Rat Model of Obesity Using Micro-CT and Histological Examinations.
    Gut Liver 2017 Jul 28. Epub 2017 Jul 28.
    Digestive Disease Center, Department of Internal Medicine, Inha University School of Medicine, Incheon, Korea.
    Background/aims: Botulinum toxin type A (BTX), a long-acting inhibitor of muscular contraction in both striated and smooth muscles, is responsible for gastric motility. The aim of this study was to investigate the effects of an endoscopic intragastric BTX injection on weight loss, body fat accumulation, and gastric emptying time.

    Methods: The BTX group consisted of 15 obese rats in which 20 U of BTX were injected into the gastric antrum. Read More

    Modification of Chin Projection and Aesthetics With OnabotulinumtoxinA Injection.
    JAMA Facial Plast Surg 2017 Jul 27. Epub 2017 Jul 27.
    Lasky Clinic, Beverly Hills, California2Department of Otolaryngology-Head and Neck Surgery, Keck School of Medicine of the University of Southern California, Los Angeles.
    Importance: Because of the soft-tissue envelope and the dimensional complexity of the muscular contraction of the mentalis muscle, the projection and shape of the chin is not determined by only the bony projection. In a subset of patients with a seemingly underprojected chin, a hyperactive, high-riding mentalis muscle contributes to a blunted chin contour.

    Objective: To evaluate the use of onabotulinumtoxinA (botulinum toxin A) for improving chin aesthetics in patients with an underprojected bony chin and a high-riding hyperactive mentalis muscle. Read More

    Using family and staff experiences of a botulinum toxin-A service to improve service quality.
    Child Care Health Dev 2017 Jul 26. Epub 2017 Jul 26.
    Kids Rehab, The Children's Hospital at Westmead, Sydney, NSW, Australia.
    Background: The decision for families to proceed with botulinum toxin-A (BoNT-A) injections for managing childhood conditions involving hypertonia can be complex. Family-centred care is a service model that facilitates supporting families in this decision-making process. Understanding families' experiences of services is critical to developing family-centred care. Read More

    Facial Assessment and Injection Guide for Botulinum Toxin and Injectable Hyaluronic Acid Fillers: Focus on the Upper Face.
    Plast Reconstr Surg 2017 Aug;140(2):265e-276e
    São Paulo, Brazil; Montreal, Quebec, Canada; Milan, Italy; and Boca Raton, Fla. From the Clinica Dr. Maurício de Maio; The Westmount Institute of Plastic Surgery; Istituto Dermatologico Europeo; and Aesthetic Eyelid Plastic Surgery.
    Techniques for the administration of injectable fillers and neuromodulators for facial aesthetic rejuvenation and enhancement continue to evolve. As the number of physicians with limited experience in providing aesthetic treatments expands, the need for guidance and training from more experienced injectors has become apparent. The use of a slow, careful, and methodical injection technique is imperative in all treatment settings and for all facial areas. Read More

    Is repeat Botulinum Toxin A injection valuable for neurogenic detrusor overactivity-A systematic review and meta-analysis.
    Neurourol Urodyn 2017 Jul 26. Epub 2017 Jul 26.
    Department of Urology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, People's Republic of China.
    Aim: To investigate the value of repeat botulinum toxin A (BTX-A) injections in patients with neurogenic detrusor overactivity (NDO).

    Methods: We searched the PubMed, EMBASE, and EBSCO databases for articles published until June 2016. Studies that reported the efficacy and safety of repeat BTX-A injections for adult patients with NDO were eligible. Read More

    Long-term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity.
    Neurourol Urodyn 2017 Jul 26. Epub 2017 Jul 26.
    Medical School Paris Île-de-France Ouest, Inserm U1179, Versailles Saint-Quentin University, Versailles, France.
    Aims: Aims of this study were to assess the long-term outcomes of Intradetrusor injection of OnabotulinumtoxinA (Botox® injection) associated with clean intermittent-catheterization (CIC) for the treatment of neurogenic detrusor overactivity (NDO) and to identify risk factors for failure.

    Methods: Neurological patients with NDO using CIC who had received Botox® injections between January 2001 and September 2013 were included. Clinical, urodynamic and radiological data were recorded. Read More

    Lakartidningen 2017 Jul 24;114. Epub 2017 Jul 24.
    Laboratoriemedicin - Medicinsk mikrobiologi Lund, Sweden Laboratoriemedicin - Medicinsk mikrobiologi Lund, Sweden.
    Infant botulism - why honey should be avoided for children up to one year Infant botulism means that Clostridium botulinum colonize and produce toxin in the infant gut, usually during the first year of life. Illness severity varies widely and the incidence may be under-estimated. Infant botulism should be considered in cases of acute muscle weakness or floppiness in infants, especially when accompanied by constipation or feeding difficulties. Read More

    Strategies to decrease injection site pain in botulinum toxin therapy.
    J Neural Transm (Vienna) 2017 Jul 24. Epub 2017 Jul 24.
    Movement Disorders Section, Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
    Botulinum toxin is now used for numerous indications including dystonias, spasticity, cerebral palsy, hyperhidrosis, cosmetics and chronic migraine. It has to be injected into its target tissues thus causing injection site pain. We wanted to compare the efficacy of various analgesic interventions suggested for reduction of injection site pain. Read More

    Botulinum Toxin A as an Adjunct to Abdominal Wall Reconstruction for Incisional Hernia.
    Plast Reconstr Surg Glob Open 2017 Jun 21;5(6):e1358. Epub 2017 Jun 21.
    Digestive Disease Center, Bispebjerg Hospital, University of Copenhagen, Copenhagen NV, Denmark; and Department of Surgery, Zealand University Hospital, Køge, Denmark.
    Background: Repair of large incisional hernias remains a surgical and costly challenge. Temporary paralysis of the lateral abdominal wall muscles with topical administration of botulinum toxin A (BTA) is a new therapeutic concept, which may obviate the need for component separation technique (CST) for repair of large incisional hernias. Current literature on the administration of BTA as adjunct to surgical repair of abdominal incisional hernias was investigated. Read More

    TFOS DEWS II iatrogenic report.
    Ocul Surf 2017 Jul 20;15(3):511-538. Epub 2017 Jul 20.
    Aston University, Birmingham, UK.
    Dry eye can be caused by a variety of iatrogenic interventions. The increasing number of patients looking for eye care or cosmetic procedures involving the eyes, together with a better understanding of the pathophysiological mechanisms of dry eye disease (DED), have led to the need for a specific report about iatrogenic dry eye within the TFOS DEWS II. Topical medications can cause DED due to their allergic, toxic and immuno-inflammatory effects on the ocular surface. Read More

    1 OF 364